Evidence map›Paper›PMID 41910707›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Molecular subtyping-guided precision therapy for ESCC: biomarker-driven strategies and clinical translation pathways.

Huifang Lv, Wanying Zhao, Sai-Qi Wang, Xiao-Bing Chen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huifang Lv *Henan Province Engineering Research Center for of Intractable Digestive Tract Tumor Precision Therapy, Henan Province Engineering Technology Research Center for Digestive Tract Tumor Precision Therapy, Zhengzhou Key Laboratory of Precision Therapy of Gastrointestinal Cancer, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, China.
Wanying Zhao *Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Henan Key Laboratory of Cancer Epigenetics, College of Clinical Medicine, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471000, China.
Sai-Qi WangHenan Province Engineering Research Center for of Intractable Digestive Tract Tumor Precision Therapy, Henan Province Engineering Technology Research Center for Digestive Tract Tumor Precision Therapy, Zhengzhou Key Laboratory of Precision Therapy of Gastrointestinal Cancer, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, China.
Xiao-Bing ChenHenan Province Engineering Research Center for of Intractable Digestive Tract Tumor Precision Therapy, Henan Province Engineering Technology Research Center for Digestive Tract Tumor Precision Therapy, Zhengzhou Key Laboratory of Precision Therapy of Gastrointestinal Cancer, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, China. zlyychenxb0807@zzu.edu.cn.ORCID http://orcid.org/0000-0002-6831-1417

Funding

Director's Foundation of the State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer No.2025GAQZ-MS-07Henan Province Triple-100 Program: Overseas Fellowship for Medical Science and Technology Talents HNMOT2024015High-Level Talent International Training and Support Program of Henan Province 53Industry-University-Research Innovation Fund for Chinese Universities 2025MR025Medical Science and Technique Foundation of Henan Province SBGJ202301004Medical Science and Technique Foundation of Henan Province SBGJ202302029National Natural Science Foundation of China 82103560National Natural Science Foundation of China 82573686Natural Science Foundation of Henan Province 232300421119Science and Technology Research and Development Program Joint Fund of Henan Province 235200810034
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with significant geographical disparities, particularly high in East Asia. The prognosis for advanced patients remains poor, largely due to profound intertumoral and intratumoral molecular heterogeneity, which drives variable treatment responses. This review delineates progress in molecular classification, where multiomics studies have defined distinct subtypes-cell cycle activated (CCA), NRF2-oncogenic activated (NRFA), immune suppressive (IS), and immune modulatory (IM)-each with specific therapeutic implications. This framework guides targeted therapies and predicts immunotherapy outcomes. We further evaluate biomarker-driven strategies (PD-L1, TMB, and NOTCH1 mutations) and emerging therapies targeting driver genes and the metabolic microenvironment. Translating subtyping into clinical practice requires validating strategies through innovative trial designs, establishing dynamic monitoring using liquid biopsy and spatial multiomics, and integrating multidimensional biomarkers. Constructing a molecular subtype-based precision medicine framework is pivotal to overcoming therapeutic limitations and improving survival in ESCC.

Indexed as

Biomarkers, TumorEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaPrecision MedicineHumansMolecular Targeted TherapyPrognosisTumor MicroenvironmentBiomarkers, TumorBiomarkersEsophageal squamous cell carcinomaMolecular subtypesPrecision therapyTumor microenvironment

Identifiers

PMID41910707

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.